

**COPY OF PAPERS  
ORIGINALLY FILED**

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**

Substitute for form 1449A/PTO				Complete If Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				Application Number	10/071032
				Filing Date	February 8, 2002
				First Named Inventor	Richard Dennis Dyer, et al
				Group Art Unit	Unknown
				Examiner Name	Unknown
				Attorney Docket Number	A0000425-01-CFP
Sheet	1	of	3		

Examiner Signature	<i>Allen</i>	Date Considered	5/12/04
-----------------------	--------------	--------------------	---------

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 1). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.  
**DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

**COPY OF PAPERS  
ORIGINALLY FILED**

PTO/SB/08B (08-00)

Anonymized for use through 10/31/2002. OMB 0651-0031  
U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Please type a plus sign (+) inside this box → +

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 14-98/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

3

**Complete If Known**

Application Number	10/071032
Filing Date	February 8, 2002
First Named Inventor	Richard Dennis Dyer, et al
Group Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	A0000425-01-CFP

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
TNT	✓	MONTANA, John, et al, "The design of selective non-substrate-based matrix metalloproteinase inhibitors", Current Opinion in Drug Discovery & Development, 2000; 3(4), pp 353-361 ,	
	✓	CLAES, K., Ian, et al, "Matrix metalloproteinase inhibitors in the treatment of arthritis", Current Opinions in Anti-Inflammatory & Immunomodulatory Investigational Drugs, 2000; 2(1), pp 16-25 ,	
	✓	CHEN, James, et al, "Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design", J. Am. Chem. Soc., 2000, 122; pp 9648-9654 ,	
	✓	DEMENT ABSTRACT, 96-068630/07, "New fused imidazole cpds. - possess inhibitory activity of adhesion molecule expression (Eng.)" , 1996 .	
TNT	✓	DEMENT ABSTRACT, 93-168431/21, "New Thiazolo-pyrimidine disone derivs. for treating arteriosclerosis" , 1993 .	
	✓	DEMENT ABSTRACT, 91-001547/01, "New sulphur-Contg. fused pyrimidine cpds. - are endothelin and interleukin inhibitors for treatment and prevention of myocardial infarction, auto:immune diseases, etc." ,	
	✓	DEMENT ABSTRACT, 93271 E/44, "Cyclised pro-form of 5-flouro-uracil derivs. - are orally administered antitumour agents without side effects of parent" ,	
TNT	✓	KALI, Ravinder, et al, "2-14C-1-Allyl-3,5-diethyl-6-chlorouracil II: Isolation and Structures of the Major Sulfur-Free and Three Minor Sulfur-Containing Metabolites and Mechanism of Biotransformation", Journal of Pharmaceutical Sciences, Vol. 71, No. 8, August 1982; pp 897-900 .	
	✓	KALI, Ravinder, et al, "Structure of a novel sulphur-containing metabolite of Acluracil (1-allyl-1,3,5-diethyl-6-chlorouracil)", Xenobiotica, 1982, Vol. 12, No. 8; pp 495-498 .	
	✓	KALI, Von R., et al, "Identifizierung eines dritten S-haltigen Metaboliten von 1-Allyl-1,3,5-diethyl-6-chloruracil und Bildungsmechanismus der SCH - Metaboliten", Arzneim.-Forsch./Drug Res., 1982; 32(I)(6); pp 610-612 .	
TNT	✓	BRUNN, et al, "The Synthesis of Some 1-Substituted Cytosine and Uracil Derivatives", J. Chem. Soc., 1977; pp 2385-2391 .	

**RECEIVED**

AUG 01 2002

**OFFICE OF PETITIONS**

Examiner:  
Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

**COPY OF PAPERS  
ORIGINALLY FILED**

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
a collection of information unless it contains a valid OMB control number.

Please type a plus sign (+) inside this box →  +

**Under the Paperwork Reduction Act of 1995,**

Substitute for form 1449B/PTO

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 3

**Complete If Known**

Application Number	10/071032
Filing Date	February 8, 2002
First Named Inventor	Richard Dennis Dyer, et al
Group Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	A0000425-01-CFP

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

**Examiner  
Signature**

*M. L. M.*

Date  
Considered

5/12/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
www.uspto.gov/patents/Trademarks/TrademarksWithOMBCapitalLetters

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Sheet 1 of 3 Attorney Docket Number A0000425-01-CFP

**Complete if Known**

<b>Application Number</b>	10/071032
<b>Filing Date</b>	February 8, 2002
<b>First Named Inventor</b>	Richard Dennis Dyer, et al
<b>Group Art Unit</b>	Unknown
<b>Examiner Name</b>	Unknown
<b>Attorney Docket Number</b>	A0000425-01-CFP

## **U.S. PATENT DOCUMENTS**

Draft  
of  
Page #5

## **FOREIGN PATENT DOCUMENTS**

Examiner Signature		Date Considered	5/12/04
-----------------------	---	--------------------	---------

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kind of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08B (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

### Complete if Known

Application Number	10/071032
Filing Date	February 8, 2002
First Named Inventor	Richard Dennis Dyer, et.al
Group Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	A0000425-01-CFP

### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		MONTANA, John, et al, "The design of selective non-substrate-based matrix metalloproteinase inhibitors", Current Opinion in Drug Discovery & Development, 2000; 3(4), pp 353-361	
		CLARK, Ian, et al, "Matrix metalloproteinase inhibitors in the treatment of arthritis", Current Opinions in Anti-inflammatory & Immunomodulatory Investigational Drugs, 2000; 2(1), pp 16-25	
		CHEN, James, et al, "Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design", J. Am. Chem. Soc., 2000, 122; pp 9648-9654	
		DERWENT ABSTRACT, 96-068630/07, "New fused imidazole cpds. - possess inhibitory activity of adhesion molecule expression (Eng.)"	
		DERWENT ABSTRACT, 93-168431/21, "New Thiazolo-pyrimidine disone derivs. for treating arteriosclerosis"	
		DERWENT ABSTRACT, 91-001547/01, "New sulphur-Contg. fused pyrimidine cpds. - are endothelin and interleukin inhibitors for treatment and prevention of myocardial infarction, auto:immune diseases, etc."	
		DERWENT ABSTRACT, 93271 E/44, "Cyclised pro-form of 5-fluoro-uracil derivs. - are orally administered antitumour agents without side effects of parent"	
		KAUL, Ravinder, et al, "2-14C-1-Allyl-3,5-diethyl-6-chlorouracil II: Isolation and Structures of the Major Sulfur-Free and Three Minor Sulphur-Containing Metabolites and Mechanism of Biotransformation", Journal of Pharmaceutical Sciences, Vol. 71, No. 8, August 1982; pp 897-900	
		KAUL, Ravinder, et al, "Structure of a novel sulphur-containing metabolite of Acluracil (1-allyl-3,5-diethyl-6-chlorouracil)", Xenobiotica, 1982, Vol. 12, No. 8; pp 495-498	
		KAUL, Von R., et al, "Identifizierung eines dritten S-haltigen Metaboliten von 1-Allyl-3,5-diethyl-6-chloruracil und Bildungsmechanismus der SCH - Metaboliten", Arzneim. Forsch./Drug Res., 1982; 32(I)(6); pp 610-612	
		BROWN, et al, "The Synthesis of Some 1-Substituted Cytosine and Uracil Derivatives", J. Chem. Soc., 1972; pp 2385-2391	

Examiner Signature

Date Considered

5/12/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08B (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031

Approved for use through 10/31/2002. GMB 0851-0031  
U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE  
U. S. GOVERNMENT PRINTING OFFICE: 2002 50-130-000  
GPO: 2002 50-130-000

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**

**Substitute for form 1449B/PTO**

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 3

<i><b>Complete if Known</b></i>	
Application Number	10/071032
Filing Date	February 8, 2002
First Named Inventor	Richard Dennis Dyer, et al
Group Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	A0000425-01-CFP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Signature		Date Considered	5/12/04
-----------------------	---	--------------------	---------

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**1 Unique citation designation number**       **3 Applicant is to place a check mark here if English language Translation is attached.**

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Sheet 1 of 1

#13

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. <b>A0000425-01-CFP</b>	SERIAL NO. <b>10/071,032</b>
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)		APPLICANT <b>Richard Dennis Dyer, et al.</b>	
		FILING DATE <b>February 08, 2002</b>	GROUP <b>1624</b>

RECEIVED  
2003

## **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc)**

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ANY COPIES OF DOCUMENTS LISTED ON THIS FORM PTO-1449 SHOULD HAVE CERTAIN INFORMATION PLACED ALONG THE LEFT SIDE OF THE DOCUMENT. INFORMATION SUCH AS DOCKET NUMBER, FILING DATE, SERIAL NUMBER, ART UNIT, ETC.